This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

More Hep C Drug Abstracts Leak Ahead of EASL Confab

BOSTON ( TheStreet) -- More hepatitis data supposedly kept under wraps by the European Association for the Study of the Liver (EASL) in advance of next week's closely followed annual meeting has made its way into the hands of Wall Street investors.

Fortunately for EASL, the leaked research abstracts, including one describing the important "Electron" study of Gilead Sciences' (GILD - Get Report) hepatitis C drug GS-7977, doesn't contain new information and therefore isn't particularly stock moving.

On Tuesday, an investor who asked to remain anonymous emailed me three research abstracts involving hepatitis C drug data from Gilead Sciences and Bristol-Myers Squibb (BMY - Get Report). All of the abstracts were supposed to be embargoed and therefore not publicly available, according to EASL rules.

One of these abstracts, titled "Electron: Once Daily PSI-7977 Plus RBV in HCV GT1/2/3" is the subject of intense investor interest because it will help assess the efficacy of Gilead's most important hepatitis C drug, acquired through the $11 billion acquisition of Pharmasset.

EASL officials confirmed the authenticity of the leaked research abstracts via email but requested that specific information contained in the abstracts not be disclosed. I'm abiding by EASL's request because the leaked abstracts are not much more than placeholders containing early, incomplete and previously announced data that will only be updated at the EASL meeting April 18-22.

The embargoed abstract for Gilead's Electron study, for example, describes but doesn't contain any specific data on response rates involving GS-7977 and treatment-naive, genotype 1 hepatitis C patients. The performance of GS-7977 in this group of hepatitis C patients is among the most highly anticipated data presentations expected at the EASL meeting.

The EASL meeting is where Gilead Sciences, Bristol, Abbott (ABT - Get Report), Idenix Pharmaceuticals (IDIX), Vertex Pharmaceuticals (VRTX - Get Report) and Johnson & Johnson (JNJ - Get Report) are among the companies expected to present new clinical data on experimental hepatitis C therapies. Therefore, the meeting is as vitally important to hepatitis C doctors and patients as it is to investors.

How a select set of confidential, embargoed hepatitis C drug abstracts came into the hands of some Wall Street investors hasn't been fully explained. The blame most likely lies with EASL, which apparently failed to wall off the select set of abstracts when the group posted most of the abstracts online April 4. EASL later realized its error and was able to yank the embargoed abstracts from its web site, but not before some people, including some investors, were able to download them.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ABT $43.58 -3.80%
BMY $58.23 -2.10%
GILD $101.47 -3.40%
JNJ $92.15 -1.90%
IDIX $24.50 0.20%

Markets

Chart of I:DJI
DOW 16,058.35 -469.68 -2.84%
S&P 500 1,913.87 -58.31 -2.96%
NASDAQ 4,636.1050 -140.4030 -2.94%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs